Impersonal research, traced to filings. An evidence-first read of whether LyondellBasell's move up the value chain is real, well-stewarded, and still underappreciated — the same for every reader, from SEC EDGAR 10-K + 8-K filings. This is not personalized advice or a recommendation to any specific person. As of 24 Jul 2026. Disclosures.
Why we pass
TRIGGERED (planted commodity control, confirmed by the filings). LYB's earnings are driven by the olefin/polyolefin and refining spread cycle, not a structural mix-shift up the value chain. The 10-K's first risk factor is industry 'cyclicality and volatility'; margins swung OPM 14.7% (2021) -> -1.4% (2025) and ROCE 22.9% -> -1.5% with the commodity cycle, culminating in a FY2025 net loss of $(738)M, a $1,182M impairment, deferred growth capex, and a ~50% dividend cut. Management itself concedes the 'commodity nature of many of our products' and competition 'based primarily on price'. The Circulen/MoReTec circularity move is a real but immaterial up-chain shoot (~15% of 2026 capex, MoReTec-1 not online until 2027, MoReTec-2 FID postponed) — nowhere near material enough to reclassify the business as a structural value-migrator. Must rank low.
veto: cyclical_not_structural
How it scores
Seven dimensions, 0–5 — the baseline everyone has (28%) plus the revealed-behaviour Analysis Bridge (72%). The method →
Baseline
Analysis Bridge
The evidence, dimension by dimension
Execution (do-side)
2/5Execution is competent on COST (cash plan beat: $800M vs $600M target; refinery exit; portfolio pruning) but the operating record is deteriorating and cyclical, not compounding: OPM collapsed 14.7% (2021) -> 5.7% (2024) -> -1.4% (2025); ROCE 22.9% -> -1.5%; FY2025 net loss $(738)M with a $1,182M impairment (European petchem + auto downturn). Up-chain projects (Flex-2, MoReTec-2) were deferred, not executed. Execution is defensive/downcycle management, not delivery of a value-migration.
Say/do credibility
2/5Mixed say/do, weighted down by the biggest promise broken: the ~50% dividend cut (Feb 2026) contradicts years of dividend-growth positioning — the single most credibility-damaging event in the file. Offsetting positive: the cash-savings target was beaten ($800M vs $600M), so management is honest and capable on costs. But growth/upgrade and prior circularity ambitions were deferred or rebased. Net: reliable on defensive cost promises, unreliable on the growth/returns promises that a value-migration thesis needs. Guidance weighted DOWN by track record.
Strategy — IP & partnerships
2/5Genuine strategic intent up-chain exists (CLCS/Circulen, proprietary MoReTec recycling technology, polyolefin process-technology licensing) and this is more than a pure commodity control has. But it is immaterial to results today (~15% of 2026 capex; MoReTec-1 not online until 2027; MoReTec-2 FID postponed) and the core is self-admittedly undifferentiated commodity ('commodity nature of many of our products'; competition 'based primarily on price'). Strategy is directionally right but early and under-funded during the downturn.
Governance & stewardship
3/5Sound, orthodox large-cap governance: investment-grade balance sheet defended, experienced sector-veteran executive team (CEO Vanacker ex-Neste; CFO ex-BASF), transparent disclosure of impairments/closures and the dividend cut, clean Code of Conduct/human-rights framework. Capital allocation is disciplined-but-cyclical (cut dividend to protect the rating rather than lever up). No governance red flags in the filing; neither is there any governance feature that advantages a value-migration. Average.
Margins over the cycle
Operating margin and return on capital across the last decade of SEC filings. A structural climb up the value chain holds its gains through the down-cycle; a commodity name gives them back. Structural vs cyclical →
From SEC EDGAR XBRL.
The say/do credibility ledger
What management promised, versus what the filings show they delivered — the single largest weight in the read.
| Promise | When | Status | What the filings show |
|---|---|---|---|
| Cash improvement plan targeting a $600 million run-rate in annualized savings for 2025 (announced to address macro volatility) | 2025-04 (announced April 2025) | Delivered | 'As of the end of 2025, the cash improvement plan achieved $800 million in annualized cash savings relative to our 2025 plan' — beat the $600M target. Credible on cost-cutting execution. 10-K FY2025, Item 7 MD&A (Cash Improvement Plan) |
| Maintain/grow the dividend (LYB historically marketed a rising, aristocrat-style dividend) | prior years (implicit capital-allocation commitment) | Missed | 'In February 2026, we declared a quarterly dividend of $0.69 per share, representing a $0.68 per share reduction from our fourth quarter 2025 dividend' — a ~50% cut, the clearest say/do failure in the file: the payout promise broke under the commodity downturn. 10-K FY2025, Item 7 MD&A (Dividends) |
| Deliver planned growth/upgrade capex (Flex-2 Channelview, MoReTec-2, PO/TBA economics) | prior years | Missed | 'we announced the deferral of construction on our Flex-2 project in Channelview to preserve capital during the market downturn and also postponed the final investment decision on... MoReTec-2'; 'higher costs arising from delaying construction of our PO/TBA plant in Houston impacted our projected rate of return'. Growth commitments were pulled when the cycle turned. 10-K FY2025, Item 1A Risk Factors (capital projects) |
| Circularity ambition — recycled/renewable polymers scale-up (prior target revised) | 2026 (ambition updated in 2026 10-K; MoReTec-1 startup pledged 2027) | In progress | Ambition RESET to 'produce and market 800 thousand metric tons of recycled and renewable-based polymers annually by 2030' (prior ambition revised down/rebased). MoReTec-1 'targeted startup... set for 2027' and MoReTec-2 FID postponed — the up-chain move is real but not yet material to revenue or margin. 10-K FY2025, Item 7 MD&A (Sustainability; circularity ambition updated in 2026) |
| Deliver additional $500M cash savings in 2026 for a cumulative $1.3bn target | 2026-02 (in FY2025 10-K) | Too early | 'For 2026, we expect to generate an additional $500 million of cash savings relative to 2025 actuals for a cumulative target of $1.3 billion' — forward guidance, not yet delivered. 10-K FY2025, Item 7 MD&A (Cash Improvement Plan) |
Triangulation chain
A real migration lights up all five: stated → approved → funded → permitted → protected. An announced-only one stalls early.
Three strategic pillars articulated: 'Growing and upgrading the core', 'Building a profitable Circular & Low Carbon Solutions (CLCS) business', and 'Step up Performance and Culture'. CLCS targets 800 thousand metric tons of recycled/renewable-based polymers annually by 2030 (a genuine up-chain intent). But the core business self-describes as commodity: products compete 'primarily on price' due to 'the commodity nature of many of our products'. (10-K FY2025, Item 1 Business (Strategy) + Item 7 MD&A (Sustainability) + Item 1A Risk Factors ('We sell products in highly competitive global markets'))
Board-level capital allocation is explicit: MoReTec-1 chemical-recycling plant (Wesseling, Germany) approved and under construction, startup targeted 2027. But approvals are being REVERSED under the downturn: Flex-2 (Channelview) construction deferred, MoReTec-2 final investment decision postponed, Maasvlakte PO/SM permanently closed, Houston refinery permanently shut Q1 2025, and European O&P assets (Berre, Munchsmunster, Carrington, Tarragona) put up for sale. The revealed do-side is retrenchment, not up-chain investment. (10-K FY2025, Item 1A Risk Factors ('deferral of construction on our Flex-2 project... postponed the final investment decision on... MoReTec-2'; 'permanent closure of the PO/SM production unit at the Maasvlakte site') + Item 7 (Houston refinery shutdown))
Investment-grade balance sheet, $3,750M undrawn revolver + $900M receivables facility fully available at 2025-12-31. But FY2025 was a net LOSS of $(738)M and free cash flow is strained: a cash improvement plan was launched (Apr 2025) to preserve capital, and only ~15% of the 2026 capital budget is earmarked for sustainability/CLCS. The dividend was CUT 50% (to $0.69 from $1.37) in Feb 2026 to conserve cash. Funding exists but is being rationed toward survival, not up-chain growth. (10-K FY2025, Item 7 MD&A (Liquidity; 'delaying certain sustainability-related capital projects to preserve capital during the cycle downturn'; dividend reduction) + Item 1A ($3,750M revolver undrawn))
Operates a permitted Gulf Coast / European site network; MoReTec-1 permitted and in construction at Wesseling. No permitting is a differentiator here — these are legacy petrochemical sites; the filing flags permits as a risk (renewal/revocation, climate/REACH/TSCA restrictions), not a moat. (10-K FY2025, Item 1 (Description of Properties) + Item 1A Risk Factors (permits 'subject to renewal, modification and... revocation'))
Owns proprietary MoReTec chemical-recycling technology and licenses polyolefin process technology to third parties (a real IP asset). However, for the bulk of revenue the filing concedes there is little protection: 'Due to the commodity nature of many of our products' the company 'may not be able to pass on cost increases' and cannot 'protect our market position... by product differentiation'. IP is narrow relative to the commodity core. (10-K FY2025, Item 1A Risk Factors ('commodity nature of many of our products'; polyolefin process technology licensing) + Item 7 (MoReTec proprietary technology))
Catalysts
- MoReTec-1 chemical-recycling plant startup (Wesseling, Germany), enabled by EU circularity/regulatory demand for recycled content · 2027 (targeted)
The only genuine up-chain catalyst; would begin to prove the CLCS pillar. Immaterial to consolidated results until well after startup.
- European O&P asset divestiture (Berre, Munchsmunster, Carrington, Tarragona) + Houston refinery / Maasvlakte closures — shrinking the commodity footprint · closing expected Q2 2026
Portfolio pruning to defend returns; reduces cyclicality exposure but is retrenchment, not up-chain growth.
Risk flags
- cyclical_not_structural
TRIGGERED (planted commodity control, confirmed by the filings). LYB's earnings are driven by the olefin/polyolefin and refining spread cycle, not a structural mix-shift up the value chain. The 10-K's first risk factor is industry 'cyclicality and volatility'; margins swung OPM 14.7% (2021) -> -1.4% (2025) and ROCE 22.9% -> -1.5% with the commodity cycle, culminating in a FY2025 net loss of $(738)M, a $1,182M impairment, deferred growth capex, and a ~50% dividend cut. Management itself concedes the 'commodity nature of many of our products' and competition 'based primarily on price'. The Circulen/MoReTec circularity move is a real but immaterial up-chain shoot (~15% of 2026 capex, MoReTec-1 not online until 2027, MoReTec-2 FID postponed) — nowhere near material enough to reclassify the business as a structural value-migrator. Must rank low.
Sources
Bridged from SEC EDGAR 10-K + 8-K filings, latest 10-K filed 20 Feb 2026. Read the 10-K on SEC EDGAR → Provenance: agent-grounded-fulltext. Financials from SEC EDGAR XBRL; price from public market data.